Celanese and Secarna Pharmaceuticals collaborate for RNA research for antisense therapies

Lonza to buy US biologics site from Roche for US$ 1.2 billion

Lonza plans to invest approximately CHF 500 million to upgrade the facility

Venus Remedies secures regulatory approvals for three key oncology drugs in Ukraine

Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy

CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product

Cureskin secures US$ 20 million in Series B funding

Cureskin aims to disrupt the large and growing skin and hair care industry in India

Merck plans to conduct clinical trials of a novel investigational HPV vaccine for GARDASIL9

Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers

Nirma acquires majority stake in Glenmark Life Sciences

Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals

Venus Remedies gets huge global acclaim with UNICEF GMP approval

Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF

Merck completes acquisition of Harpoon Therapeutics

Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager

CAPFIMS to provide opportunity for medical graduates and specialists to serve in the medical cadre of CAPFs

The Cabinet has approved budgetary support of Rs. 2207.50 crore in the 15th Finance Commission Cycle to run CAPFIMS as a campus of AIIMS, New Delhi.